Telios Pharma, Inc.
Telios Pharma, Inc.
Explore linked clinical trials.3 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis | Conjunctival Diseases, Conjunctivitis, Allergic, Hypersensitivity, Immediate, conjunctivitis, eye disorder, immune system disorder | Recruiting | Phase 2 | 2025-11-25 | NCT07220408 | |
| Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis | Conjunctival Diseases, Conjunctivitis, Allergic, Hypersensitivity, Immediate, conjunctivitis, eye disorder, immune system disorder | Recruiting | Phase 2 | 2024-11-13 | NCT06686472 | |
| Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2023-02-21 | NCT05280509 |